Near Real-Time Surveillance of Stimulants in the Overdose Crisis – Drug Overdose Toxico-Surveillance (DOTS) Expansion
Closed Special Notice Posted
- Solicitation number
- 75F40123R00116
- Agency
-
Office of Operations
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541 Professional, Scientific, and Technical Services
- Place of performance
- Silver Spring, Maryland 20993, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The US Food and Drug Administration (FDA) intends to award a sole source contract to the American College of Medical Toxicology to provide real-time information on the fourth wave of the overdose crisis and the impact of stimulant co-consumption. The contract is expected to be awarded by August 02, 2023. The FDA will consider all responses received prior to the closing date of this notice to determine whether it is necessary to use full and open competition for this requirement.
Services to be provided by the contractor:
- Provision of real-time information on the fourth wave of the overdose crisis.
- Analysis of the impact of stimulant co-consumption.
- Regular reporting to the FDA.
- Data collection and analysis.
- Consultation and advice on the overdose crisis and stimulant co-consumption.
Notice text
Notice of Intent Sole Source
This announcement is not a Request for Proposal.
The US Food and Drug Administration {FDA), Office of Finance Budget Acquisition and Planning, intends to award a sole source award to American College of Medical Toxicology, a current incumbent contract holder; to provide the detailed real-time information on the fourth wave of the overdose crisis and the impact of stimulant co-consumption at;
The US Food and Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring MD 20993
The propose simplified acquisition is for services; the Government intends to solicit and negotiate to only one source. Interested parties may identify their interests and capabilities to respond to the requirement within seven (7) days after the publication of this notice. A determination by the Government not to compete this proposed simplified acquisition based upon responses to this notice, is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive requirement. No further solicitation is available.
FDA will consider all responses received prior to the closing date of this notice and will use responses in determining, whether it is necessary to use full and open competition for this requirement. Responses shall be emailed to Natapol Sirikhan, Natapol.Sirikhan@fda.hhs.gov, by August, 02, 2023, 12:00 PM EST.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity